Circulating miRNA markers show promise as new prognosticators for multiple myeloma

Leukemia

Volumn 28, Issue 9, 2014, Pages 1922-1926

  Rocci, A ^a   Hofmeister, C C ^b   Geyer, S ^b   Stiff, A ^b   Gambella, M ^a   Cascione, L ^c,d   Guan, J ^c   Benson, D M ^b   Efebera, Y A ^b   Talabere, T ^b   Dirisala, V ^b   Smith, E M ^b   Omede P ^a   Isaia, G ^e   De Luca, L ^f   Rossi, D ^g   Gentili, S ^h   Uccello, G ^h   Consiglio, J ^b   Ria, R ^h   Benevolo, G ^h   Bringhen, S ^a   Callea, V ^h   Weiss, B ⁱ   Ferro, A ^j   Magarotto, V ^a   Alder, H ^c   Byrd, J C ^b   Boccadoro, M ^b   Marcucci, G ^a   Palumbo, A ^a   Pichiorri, F ^b   more..

^a UNIVERSITY OF TURIN   (Italy)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^e UNIVERSITY OF TURIN   (Italy)

^f REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^h Italian Multiple Myeloma Network   (Italy)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF CATANIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; MICRORNA; MICRORNA 16; MICRORNA 25; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CHROMOSOME 13Q; CHROMOSOME DELETION; CREATININE BLOOD LEVEL; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENETIC RISK; GLOMERULUS FILTRATION RATE; HUMAN; LETTER; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT;

BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; HUMANS; MICRORNAS; MULTIPLE MYELOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84908275352     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.155     Document Type: Letter

References (14)

1. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ., et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011; 118: 4359-4362
2. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D., et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008; 105: 12885-12890
3. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K., et al. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer. 2009; 48: 521-531
4. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S., et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009; 114: e20-e26
5. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R., et al. Bortezomib-Melphalan-Prednisone-Thalidomide followed by maintenance with Bortezomib-Thalidomide compared with Bortezomib-Melphalan-Prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010; 28: 5101-5109
6. Pichiorri F, Okumura H, Nakamura T, Garrison PN, Gasparini P, Suh SS., et al. Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions. J Biol Chem. 2009; 284: 1040-1049
7. Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A., et al. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med. 2013; 210: 951-968
8. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515-526
9. Schemper M, Wakounig S, Heinze G. The estimation of average hazard ratios by weighted Cox regression. Stat Med. 2009; 28: 2473-2489
10. Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ., et al. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1703-1707
11. Jung SH, Yang DH, Ahn JS, Lee SS, Ahn SY, Kim YK., et al. Decreased body mass index is associated with poor prognosis in patients with multiple myeloma. Ann Hematol. 2013; 93: 835-840
12. Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J., et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2013; 99: 511-518
13. Campo S, Allegra A, D'Ascola A, Alonci A, Scuruchi M, Russo S., et al. MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma. Br J Haematol. 2014; e-pub ahead of print 12 March. 2014; doi:10.1111/bjh.12828
14. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA. 2012; 109: E2110-E2116